This meeting took place in the past. For a complete list of the meetings for the upcoming/current season, see our meeting list or click on related meetings tab below to check for related meeting(s).
Web Desc
Epigenetic Marks and Cancer Drugs
Organizer(s): Ali Shilatifard
Date: March 20 - 25, 2013
Location: Eldorado Hotel & Spa, Santa Fe, NM, USA
Sponsored by AVEO Oncology, Celgene Corporation, Genentech, Inc. and H3 Biomedicine Inc.
Summary of Meeting:
To regulate the precise pattern of gene expression during development, eukaryotic cells have evolved to have multifaceted transcriptional machineries and chromatin states. The DNA within the eukaryotic nucleus is found in complex with histone proteins to form nucleosomes, the basic unit of chromatin. Detailed structural studies demonstrated that the N-terminal tails of each of the histones protrude outward beyond the gyres of DNA and can be posttranslationally modified. The modifications of histone tails could provide a landing pad for a diverse array of transcription factors, chromatin remodelers, and DNA-interacting proteins to regulate gene expression. Translocations and/or mutations in chromatin-modifying machineries that perturb the timing and/or pattern of gene expression can result in the pathogenesis of human diseases including cancer. Recent studies demonstrate that the misregulation of several of the histone-modifying enzymes can contribute to changes in the epigenetic state leading to disease development. Therefore, both the scientific and the pharmaceutical communities have concentrated on identifying the molecular function for many of the histone-modifying machineries and are in the process of developing small molecular inhibitors of their activities in the hope of their use for targeted therapeutics of cancer. This Keystone Symposia meeting on Epigenetic Marks and Cancer Drugs serves as a much-needed platform for bringing both the scientific and the pharmaceutical communities together to discuss recent advances in this very exciting area.
Scholarship Deadline: November 19 2012
Discounted Abstract Deadline: November 19 2012
Abstract Deadline: December 21 2012
Discounted Registration Deadline: January 22 2013
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
AVEO OncologyCelgene CorporationGenentech, Inc.H3 Biomedicine Inc.
We gratefully acknowledge additional support for this conference from:
Cell Signaling Technology, Inc.Epizyme, Inc.Novus Biologicals, Inc.ROCKLAND IMMUNOCHEMICALS, Inc.Zymo Research Corporation
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Constellation Pharmaceuticals

Epizyme, Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1R13CA177246-01
The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

No content found

No content found

No content found

No content found